Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry.

OBJECTIVE To compare the effectiveness of antihyperglycemic therapies in type 2 diabetic patients with poor glycemic control (baseline glycosylated hemoglobin [HbA1C] > 8%). STUDY DESIGN Longitudinal (cohort) study. METHODS Study patients were 4775 type 2 diabetic patients who initiated new antihyperglycemic therapies and maintained them for up to 1 year. The study setting was Kaiser Permanente Northern California Medical Group, an integrated, prepaid, healthcare delivery organization. Treatment regimens were 1 or more of the following: insulin, thiazolidinediones, sulfonylureas, biguanides (metformin), or other less frequently used options (including meglitinides or alpha-glucosidase inhibitors). RESULTS In this cohort, the mean HbA1C was 9.9% when therapy was initiated. Within 1 year, there was a drop of 1.3 percentage points in the mean HbA1C (to 8.6%), and 18% of new initiators achieved HbA1C values of < or = 7%. After adjusting for baseline clinical differences, the proportion of patients treated to goal was greatest among those receiving thiazolidinediones in combination (24.6%-25.7%) or a regimen of metformin and insulin (24.9%), while the least success was experienced by those receiving sulfonylureas alone (12.5%) or insulin-sulfonylureas regimens (10.9%). The probability of achieving the target goal was most strongly predicted by the level of glycemic control before initiation, but patient behaviors (eg, frequent self-monitoring, lower rates of missed appointments) also were strongly associated with greater levels of control. CONCLUSION Overall, therapy initiation resulted in an impressive population-level benefit. However, since most new initiators still had not achieved good control within 12 months, careful monitoring and prompt therapy intensification remain important.

[1]  Melissa M. Parker,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al. , 2004, Diabetes care.

[2]  Andrew J Karter,et al.  Missed Appointments and Poor Glycemic Control: An Opportunity to Identify High-Risk Diabetic Patients , 2004, Medical care.

[3]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[4]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[5]  D. Wysowski,et al.  Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. , 2003, Diabetes care.

[6]  G. Nichols,et al.  Slow response to loss of glycemic control in type 2 diabetes mellitus. , 2003, The American journal of managed care.

[7]  D. Nathan.  Initial Management of Glycemia in Type 2 Diabetes Mellitus , 2002 .

[8]  M. Robin DiMatteo,et al.  Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis , 2002, Medical care.

[9]  Jennifer Y. Liu,et al.  Ethnic disparities in diabetic complications in an insured population. , 2002, JAMA.

[10]  R. Riegelman,et al.  Interaction and intervention modeling: predicting and extrapolating the impact of multiple interventions. , 2002, Annals of epidemiology.

[11]  Walter C Willett,et al.  Dietary Patterns and Risk for Type 2 Diabetes Mellitus in U.S. Men , 2002, Annals of Internal Medicine.

[12]  Rury R Holman,et al.  Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). , 2002, Diabetes care.

[13]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[14]  A. Karter,et al.  Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. , 2001, Diabetes care.

[15]  V. Snow,et al.  Physician explanations for failing to comply with "best practices". , 2001, Effective clinical practice : ECP.

[16]  J. Wogen,et al.  Utilization of oral hypoglycemic agents in a drug-insured U.S. population. , 2001, Diabetes care.

[17]  B. Anderson,et al.  Metabolic control matters: Why is the message lost in the translation? The need for realistic goal-setting in diabetes care. , 2001, Diabetes care.

[18]  Jennifer Y. Liu,et al.  Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. , 2001, The American journal of medicine.

[19]  M. Kalis,et al.  Patient‐Reported Adherence to Guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2001, Pharmacotherapy.

[20]  K. Koh,et al.  STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. , 2001, Clinical therapeutics.

[21]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[22]  J. Izzo,et al.  Treatment of hypertension in a managed care setting. , 2001, The American journal of managed care.

[23]  Jan A Staessen,et al.  How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2) , 2001, Current controlled trials in cardiovascular medicine.

[24]  W. Insull,et al.  Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks , 2001 .

[25]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[26]  A. Karter,et al.  Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. , 2000, Diabetes care.

[27]  L. Phillips,et al.  Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. , 1999, Diabetes care.

[28]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[29]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[30]  K. Flegal,et al.  Racial and ethnic differences in glycemic control of adults with type 2 diabetes. , 1999, Diabetes care.

[31]  W. Manning,et al.  Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.

[32]  J. Colwell.  Controlling type 2 diabetes: are the benefits worth the costs? , 1997, JAMA.

[33]  U. Kabadi,et al.  Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.

[34]  P. Kronsbein,et al.  Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients , 1995, Acta Diabetologica.

[35]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[36]  R M Poses,et al.  Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data? , 1995, Medical care.

[37]  L. Delahanty,et al.  The Role of Diet Behaviors in Achieving Improved Glycemic Control in Intensively Treated Patients in the Diabetes Control and Complications Trial , 1993, Diabetes Care.

[38]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.

[39]  N. Krieger.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.

[40]  S. Genuth,et al.  Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group , 1987, Diabetes Care.

[41]  M S Kramer,et al.  Scientific challenges in the application of randomized trials. , 1984, JAMA.

[42]  R. Hiatt,et al.  Characteristics of patients referred for treatment of end-stage renal disease in a defined population. , 1982, American journal of public health.

[43]  Arshag D Mooradian,et al.  Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2002, Diabetes care.

[44]  Paula Williams,et al.  Stress management improves long-term glycemic control in type 2 diabetes. , 2002, Diabetes care.

[45]  J. Wofford.  Clinical inertia. , 2002, Annals of internal medicine.

[46]  D. Nathan.  Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. , 2002, The New England journal of medicine.

[47]  Anson,et al.  DIET , LIFESTYLE , AND THE RISK OF TYPE 2 DIABETES MELLITUS IN WOMEN , 2001 .

[48]  W. Insull,et al.  Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. , 2001, The American journal of cardiology.

[49]  康生 大久保,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .